Sphingo-guanidines and their use as inhibitors of sphingosine kinase (WO2010078247)

Expert Opinion on Therapeutic Patents

Volumn 21, Issue 5, 2011, Pages 807-812

  Sharma, Arun K ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Cancer; proliferative diseases; sphingo guanidines; sphingosine kinase; sphingosine kinase inhibitors

Indexed keywords

CERAMIDASE; DEXTRO ERYTHRO 2 N (1' CARBOXAMIDINO)SPHINGOSINE; DEXTRO ERYTHRO N,N DIMETHYLSPHINGOSINE; GUANIDINE DERIVATIVE; LCL 146; LCL 351; LEVO ERYTHRO 2 N (1' CARBOXAMIDINO)SPHINGOSINE; PHOSPHOTRANSFERASE INHIBITOR; SPHINGOGUANIDINE; SPHINGOSINE KINASE; UNCLASSIFIED DRUG; VCP 45129;

ARTICLE; BREAST CANCER; CANCER CELL; CELL MIGRATION; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HYDROGEN BOND; LYMPHOPROLIFERATIVE DISEASE; MOLECULAR LIBRARY; NEOPLASM; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ANIMALS; ENZYME INHIBITORS; GUANIDINES; HUMANS; PATENTS AS TOPIC; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); SPHINGOLIPIDS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79955112221     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.2011.573787     Document Type: Article

References (24)

1. Cuvillier O, Pirianov G, Kleuser B, et al. Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature 1996;381:800-3 (Pubitemid 26243122)
2. Taha TA, Hannun YA, Obeid LM. Sphingosine kinase: biochemical and cellular regulation and role in disease. J Biochem Mol Biol 2006;39:113-31
3. Hait NC, Oskeritzian CA, Paugh SW, et al. Sphingosine kinases, sphingosine 1-phosphate, apoptosis and diseases. Biochim Biophys Acta 2006;1758:2016-26 (Pubitemid 44879368)
4. Spiegel S, Milstien S. Sphingosine-1- phosphate: an enigmatic signaling lipid. Nat Rev Mol Cell Biol 2003;4:397-407 (Pubitemid 36565571)
5. Sweeney EA, Sakakura C, Shirahama T, et al. Sphingosine and its methylated derivative N,N-dimethylsphingosine (DMS) induce apoptosis in a variety of human cancer cell lines. Int J Cancer 1996;66:358-66 (Pubitemid 26166198)
6. Sakakura C, Sweeney EA, Shirahama T, et al. Selectivity of sphingosine-induced apoptosis. Lack of activity of DL-erythyro- dihydrosphingosine. Biochem Biophys Res Commun 1998;246:827-30 (Pubitemid 28420943)
7. Pitman MR, Pitson SM. Inhibitors of the sphingosine kinase pathway as potential therapeutics. Curr Cancer Drug Targets 2010;10:354-67
8. Wong L, Tan SS, Lam Y, Melendez AJ. Synthesis and evaluation of sphingosine analogues as inhibitors of sphingosine kinases. J Med Chem 2009;52:3618-26
9. Paugh SW, Paugh BS, Rahmani M, et al. A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia. Blood 2008;112:1382-91
10. Mathews TP, Kennedy AJ, Kharel Y, et al. Discovery, biological evaluation, and structure-activity relationship of amidine based sphingosine kinase inhibitors. J Med Chem 2010;53:2766-78
11. French KJ, Zhuang Y, Maines LW, et al. Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2. J Pharmacol Exp Ther 2010;333:129-39
12. Hengst JA, Wang X, Sk UH, et al. Development of a sphingosine kinase 1 specific small-molecule inhibitor. Bioorg Med Chem Lett 2010;20:7498-502
13. French KJ, Schrecengost RS, Lee BD, et al. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res 2003;63:5962-9 (Pubitemid 37187498)
14. Foss FW Jr, Mathews TP, Kharel Y, et al. Synthesis and biological evaluation of sphingosine kinase substrates as sphingosine-1-phosphate receptor prodrugs. Bioorg Med Chem 2009;17:6123-36
15. Maines LW, Fitzpatrick LR, Green CL, et al. Efficacy of a novel sphingosine kinase inhibitor in experimental Crohn's disease. Inflammopharmacology 2010;18:73-85
16. Maines LW, Fitzpatrick LR, French KJ, et al. Suppression of ulcerative colitis in mice by orally available inhibitors of sphingosine kinase. Dig Dis Sci 2008;53:997-1012
17. Maines LW, French KJ, Wolpert EB, et al. Pharmacologic manipulation of sphingosine kinase in retinal endothelial cells: implications for angiogenic ocular diseases. Invest Ophthalmol Vis Sci 2006;47:5022-31 (Pubitemid 46586409)
18. +/NADH and/or CoQ/CoQH2 ratios from plasma membrane electron transport may determine ceramide and sphingosine-1-phosphate levels accompanying G1 arrest and apoptosis. Biofactors 2005;25:43-60 (Pubitemid 44070832)
19. De Luca T, Bosneaga E, Morre DM, Morre DJ. Downstream targets of altered sphingolipid metabolism in response to inhibition of ENOX2 by phenoxodiol. Biofactors 2009;34:253-60
20. French KJ, Upson JJ, Keller SN, et al. Antitumor activity of sphingosine kinase inhibitors. J Pharmacol Exp Ther 2006;318:596-603 (Pubitemid 44061234)
21. Rao BD, Buttlaire DH, Cohn M. 31P NMR studies of the arginine kinase reaction. Equilibrium constants and exchange rates at stoichiometric enzyme concentration. J Biol Chem 1976;251:6981-6
22. Onda M, Yoshihara K, Koyano H, et al. Molecular recognition of nucleotides by the guanidinium unit at the surface of aqueous micelles and bilayers. A comparison of microscopic and macroscopic interfaces. J Am Chem Soc 1996;118:8524-30 (Pubitemid 26318253)
23. Lynch KR, McDonalds TL, Mathews TP, et al. Imidamide sphingosine kinase inhibitors. WO2011020116; 2011
24. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001;46:3-26 (Pubitemid 33653411)